Get the Stockscreener App
31.26
0.06%
-0.02
After Hours:
31.17
-0.09
-0.29%
Catalyst Pharmaceuticals Inc stock is traded at $31.26, with a volume of 1.89M.
It is down -0.06% in the last 24 hours and up +20.51% over the past month.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
See More
Previous Close:
$31.28
Open:
$31.28
24h Volume:
1.89M
Relative Volume:
0.96
Market Cap:
$3.83B
Revenue:
$588.99M
Net Income/Loss:
$214.33M
P/E Ratio:
18.56
EPS:
1.6844
Net Cash Flow:
$208.61M
1W Performance:
+0.26%
1M Performance:
+20.51%
6M Performance:
+34.28%
1Y Performance:
+29.66%
1-Day Range:
$31.24
$31.30
1-Week Range:
$31.00
$31.36
52-Week Range:
$19.05
$32.56
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
31.26 | 3.83B | 588.99M | 214.33M | 208.61M | 1.6844 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Technical Reactions to CPRX Trends in Macro Strategies - Stock Traders Daily
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Angelini Buyout And FIRDAPSE Settlement Reframe Catalyst Pharmaceuticals Story - Yahoo Finance
Third Avenue Management's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Angelini Pharma to buy Catalyst in deal worth $4.1 billion - MSN
Catalyst Pharmaceuticals Q1 earnings beat, Firdapse revenues rise Y/Y - MSN
Angelini Buyout And Firdapse Settlement Reframe Catalyst Pharmaceuticals Story - Sahm
Catalyst Pharmaceuticals, Inc.Common Stock (NQ: CPRX - FinancialContent
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus - Sahm
Catalyst Pharmaceuticals: Angelini Deal Caps A Potentially Better Story (NASDAQ:CPRX) - Seeking Alpha
CPRX SWOT Analysis: Strong Financials Amidst Market Challenges R - GuruFocus
Catalyst Pharmaceuticals (CPRX) Q1 EPS Beat Reinforces High Margin Bull Narratives - Sahm
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - Yahoo Finance
Trading the Move, Not the Narrative: (CPRX) Edition - Stock Traders Daily
Catalyst Pharmaceuticals earnings beat by $0.06, revenue topped estimates - Investing.com Canada
Catalyst Pharmaceuticals (CPRX) Announces Suspension of Guidance Updates - GuruFocus
Catalyst Pharmaceuticals, Inc. Q1 2026 earnings preview - MSN
CPRX Reports Impressive Q1 Revenue Growth - GuruFocus
Catalyst Pharma Reports Higher Revenue, Suspends Earnings Guidance - TipRanks
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Catalyst Pharmaceuticals 1Q EPS 50c >CPRX - Moomoo
Profit rises at Catalyst Pharmaceuticals (NASDAQ: CPRX) on Q1 2026 results - Stock Titan
Catalyst Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results - The Manila Times
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Reports Q1 Revenue $149.4M, vs. FactSet Est of $149.5M - marketscreener.com
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.79 per Share, vs. FactSet Est of $0.65 - marketscreener.com
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.79 per Share, Vs. FactSet Est of $0.65 - Moomoo
BRIEF-Catalyst Pharmaceuticals Q1 Revenue USD 149.4 Million Vs. IBES Estimate USD 148.2 Million - TradingView
Catalyst Pharma (NASDAQ: CPRX) posts Q1 profit ahead of Angelini deal - Stock Titan
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Scores 7/10 Fundamental Rating in Affordable Growth Screen - ChartMill
Angelini Pharma agrees $4.1bn Catalyst Pharmaceuticals acquisition - Yahoo Finance
Catalyst Pharmaceuticals (CPRX) Set to Report Q1 Earnings with P - GuruFocus
Catalyst FIRDAPSE Deal Extends Exclusivity To 2035 And Shapes Angelini Bid - Sahm
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc.CPRX - The AI Journal
Vanguard Group Inc. Lowers Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Buyout And FIRDAPSE Patents Reframe Investor Outlook - Yahoo Finance
Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1B - MSN
Family-run Angelini Pharma buys Catalyst Pharmaceuticals for over 4 billion - MSN
FinancialContentCatalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc.CPRX - FinancialContent
Catalyst Pharmaceuticals Cut to Neutral From Buy by Citigroup - Moomoo
MSN Money - MSN
Citigroup downgrades Catalyst Pharmaceuticals (CPRX) - MSN
CPRX Downgraded by Citigroup -- Price Target Lowered to $31.50 - GuruFocus
Citi Downgrades Catalyst Pharmaceuticals(CPRX.US) to Hold Rating, Cuts Target Price to $31.5 - Moomoo
European company to acquire Miami pharma business for $4.1 billion - The Business Journals
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):